&nbsp;

BiosimilarsEvaluationToolkit.pdf

Nov 2021

Document

BiosimilarsEvaluationReport_FR.pdf

Nov 2021

Document

BiosimilarsEvaluationToolkit_FR.pdf

Nov 2021

Regimen

BREN

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade,

Lymphoma - T-cell,

Rare Diseases

Intent: Palliative

Funding:

New Drug Funding Program

Brentuximab Vedotin - Previously Treated Primary Cutaneous Anaplastic Large Cell Lymphoma or Mycosis Fungoides

Drugs Used:

brentuximab vedotin

Quick Link(s):

Regimen Monograph

Sep 2024

Regimen

XELOX+BEVA

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

XELOX

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

oxaliplatin,

capecitabine

Quick Link(s):

Regimen Monograph, Patient Info Sheet (XELOX)

Jan 2024

Document

brad-campbell.jpg

Jan 2023

Regimen

BELZ

Cancer Type:

Endocrine,

Pancreatic Neuroendocrine,

Genitourinary,

Renal cell / Kidney

Intent: Curative, Palliative

Funding:

Exceptional Access Program

Belzutifan – For the treatment of adult patients with von Hippel-Lindau (VHL) disease, based on criteria

Drugs Used:

belzutifan

Quick Link(s):

Regimen Monograph

Jun 2025

Drug

binimetinib

Other Name(s): Mektovi®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jul 2023

Document

Breast Cancer Patient Information Sheet - Other Languages.zip

May 2023

Regimen

BEVA+PEMB(MNT)

Cancer Type:

Gynecologic,

Cervix

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Drugs Used:

pembrolizumab,

bevacizumab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

BEACOPDAC(ESC)

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

ODB - General Benefit

prednisone

Drugs Used: